ReviewCurrent treatment options in oncology2020
Advances in the Treatment of Cardiac Amyloidosis.
Review in Current treatment options in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- Mexican position paper for the diagnosis and treatment of cardiac amyloidosis.Archivos de cardiologia de Mexico · 2024Guideline
- Tailoring heart failure management in cardiac amyloidosis.Heart failure reviews · 2026Review
- Identifying implementation strategies to increase the early detection of cardiac amyloidosis: a pre-implementation study.Frontiers in cardiovascular medicine · 2026Article
- Potential Hematopoietic Effects of SGLT2 Inhibitors in Patients with Cardiac Amyloidosis.Reviews in cardiovascular medicine · 2025Article
- Advances in the Diagnosis and Management of Cardiac Amyloidosis: A Literature Review.Cardiology research · 2024Review
- Rare Variant of Hereditary Amyloid Transthyretin Cardiomyopathy Secondary to Ser97Tyr Mutation.Cureus · 2024Article
- Facilitators and Barriers of Incremental Innovation by Fixed Dose Combinations in Cardiovascular Diseases.Journal of cardiovascular development and disease · 2024Article
- Examining the Difficulties in Identifying and Handling Cardiac Amyloidosis; Acquiring Important Knowledge and Robust Treatment Methods.Cardiovascular & hematological disorders drug targets · 2024Review
- Temporal trends in the prevalence, incidence, and mortality of cardiac amyloidosis in Korea over 12 years.Epidemiology and health · 2024Article
- Cardiac amyloidosis in Latin America: Gaps and opportunities to increase awareness of the disease. Findings from the AMILO-LATAM research group.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2023Article
- Review
- Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis.Therapeutics and clinical risk management · 2023Review
- Cardiac amyloidosis: evolving pathogenesis, multimodal diagnostics, and principles of treatment.EXCLI journal · 2023Review
- Case report: Magnetocardiography as a potential method of therapy monitoring in amyloidosis.Frontiers in cardiovascular medicine · 2023Article
- A review of recent advances in the diagnosis of cardiac amyloidosis, treatment of its cardiac complications, and disease-modifying therapies.F1000Research · 2023Review
- Healthcare resource use of patients with transthyretin amyloid cardiomyopathy.ESC heart failure · 2022Article
- Transthyretin Amyloid Cardiomyopathy: Impact of Transthyretin Amyloid Deposition in Myocardium on Cardiac Morphology and Function.Journal of personalized medicine · 2022Article
- Changing paradigm in the treatment of amyloidosis: From disease-modifying drugs to anti-fibril therapy.Frontiers in cardiovascular medicine · 2022Review
- Article
- Transthyretin cardiac amyloidosis.Medicine and pharmacy reports · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
opinion statementCardiac amyloidosis is associated with a high mortality rate, a long delay between the first signs and the diagnosis but a short interval between diagnosis and death. This scenario has changed recently due to improved disease awareness among doctors and significant progress in diagnosis thanks to multimodal imaging and a multidisciplinary approach. Therefore, during the last few years, we have had access to specific therapies for those patients. Those therapies are quite different depending on the type of amyloidosis, but there has been real progress. Systemic light chain amyloidosis (AL) with cardiac involvement is the most common form of cardiac amyloidosis. The severity of heart disease dictates the prognosis in AL amyloidosis. Advances in chemotherapy and immunotherapy that suppress light chain production have improved the outcomes. These recent improvements in survival rates have enabled therapies such as implanted cardiac defibrillators and heart transplantation that were usually not indicated for patients with advanced light chain amyloid cardiomyopathy to now be applied in selected patients. For transthyretin amyloidosis (ATTR), the second most common form of amyloidosis with cardiac involvement, there is also significant progress in treatment. Until recently, we had no specific therapy for ATTR cardiomyopathy (ATTR-CM), though now disease-modifying therapies are available. Therapies that stabilize transthyretin, such as tafamidis, have been shown to improve outcomes for patients with ATTR-CM. Modern treatments that stop the synthesis of TTR through gene silencing, such as patisiran and inotersen, have shown positive results for patients with TTR amyloidosis. Significant progress has been made in the treatment of amyloid cardiomyopathy, and hopefully, we will see even more progress with the spread of those treatments. We now can be optimistic about patients with this disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.